TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27379556

Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 123

Group type: COMPARATOR
Intervention: High PTH levels
Number of subjects: 123
Study: 27379560

Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) 1.3 mg/m of body surface area
Number of subjects: 10
Study: 27379610

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated SeQuent Please drug-coated balloon (DCB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FFR-guided DCB-only PCI
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinuation after 4 weeks
Number of subjects: 46
Study: 27379823

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (target dose: 3 mg/d)
Number of subjects: 54
Study: 27379966

Group type: EXPERIMENTAL
Intervention: Digital Medicine System (DMS) with ingestible sensor and wearable sensor
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Digital Medicine System (DMS)
Number of subjects: 59
Study: 27381858

Group type: COMPARATOR
Intervention: Typical presentation and no-comorbidities
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Typical presentation and comorbidities
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Atypical presentation and no-comorbidities
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Atypical presentation and comorbidities
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Atypical presentation
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 11458

Group type: EXPERIMENTAL
Intervention: Underuse of invasive procedures
Number of subjects: 11458
Study: 27381904

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg with weekly dexamethasone 20 mg (cohort 3)
Number of subjects: 27
Study: 27382096

Group type: EXPERIMENTAL
Intervention: Bendamustine, gemcitabine, and vinorelbine (BeGEV)
Number of subjects: 59
Study: 27382289

Group type: EXPERIMENTAL
Intervention: Vilazodone 20-40 mg/day
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1373
Study: 27383993

Group type: EXPERIMENTAL
Intervention: Active tDCS and active MT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham tDCS and active MT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Active tDCS and sham MT
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham tDCS and sham MT
Number of subjects: 132
Study: 27384242

Group type: EXPERIMENTAL
Intervention: Intensive Care Infection Score (ICIS)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 301
Study: 27384417

Group type: EXPERIMENTAL
Intervention: 3.0T-MRU
Number of subjects: 20

Group type: COMPARATOR
Intervention: CTU
Number of subjects: 20
Study: 27385608

Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet (KD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-carbohydrate baseline diet (BD)
Number of subjects: 17
Study: 27385614

Group type: EXPERIMENTAL
Intervention: Predominantly nighttime feeding (pNT)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Predominantly daytime feeding (pDT)
Number of subjects: 349
Study: 27385761

Group type: EXPERIMENTAL
Intervention: Dietary acid load (measured by potential renal acid load, PRAL)
Number of subjects: 81797

Group type: EXPERIMENTAL
Intervention: Acid-base balanced diet
Number of subjects: 81797
Study: 27385763

Group type: EXPERIMENTAL
Intervention: Higher-protein, lower-carbohydrate or -fat diet during pregnancy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Higher maternal intake of animal protein
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Maternal macronutrient intake
Number of subjects: 320
Study: 27386049

Group type: EXPERIMENTAL
Intervention: One weekly low-level laser therapy treatment for six weeks
Number of subjects: 54
Study: 27386758

Group type: EXPERIMENTAL
Intervention: Standardized electronic case report forms completed by trained study coordinators, including demographic factors, medical history, processes of inpatient care, and baseline interview on time delays to hospital admission.
Number of subjects: 14326

Group type: EXPERIMENTAL
Intervention: Prospective individual patient follow-up focusing on patient health (symptoms) and vital status.
Number of subjects: 14326

Group type: EXPERIMENTAL
Intervention: Blood sampling for genetic data obtained at hospital discharge.
Number of subjects: 14326

Group type: EXPERIMENTAL
Intervention: Concurrent enrollment of patients from some European Union founding members.
Number of subjects: 14326
Study: 27386769

Group type: EXPERIMENTAL
Intervention: Val122Ile mutation
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Wild-type ATTR
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Overall U.S. ATTR patients
Number of subjects: 390

Group type: COMPARATOR
Intervention: U.S. ATTR patients
Number of subjects: 390
Study: 27387422

Group type: EXPERIMENTAL
Intervention: Hygiene-based intervention for skin and soft-tissue infection prevention; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study: 27387446

Group type: EXPERIMENTAL
Intervention: Ertumaxomab (ertu) administered intravenously in 2 cycles with ascending doses (10-500 μg) weekly for 28 days with a 21-day treatment-free interval.
Number of subjects: 14
Study: 27387922

Group type: EXPERIMENTAL
Intervention: Full set of three satiety hormones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Set of two satiety hormones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Set of one satiety hormone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High satiating food types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less satiating food types
Number of subjects: 0
Study: 27388458

Group type: EXPERIMENTAL
Intervention: Consistent condom use with paid or casual partners in the past month
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Self-perceived risk of getting STI/HIV
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Condom negotiation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Consistent condom use for vaginal sex
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Behavioural interventions on condom negotiation skills and condom use
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Biomedical interventions on STI/HIV testing and treatment
Number of subjects: 220
Study: 27388474

Group type: EXPERIMENTAL
Intervention: High-fat, high-protein (HFHP) meals with adaptive model-predictive insulin bolus
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Insulin dose adjustments for HFHP meals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fat, low-protein (LFLP) meals
Number of subjects: 10
Study: 27388490

Group type: EXPERIMENTAL
Intervention: Medical dispatchers recognizing acute stroke during emergency calls
Number of subjects: 2653

Group type: EXPERIMENTAL
Intervention: Emergency calls during daytime
Number of subjects: 2653

Group type: EXPERIMENTAL
Intervention: Final diagnosis of TIA vs. intracerebral hemorrhage (ICH)
Number of subjects: 2653
Study: 27388610

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-D) in non-obese patients
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-D) in obese patients
Number of subjects: 1278
Study: 27388672

Group type: EXPERIMENTAL
Intervention: TREAT subjects (polyarticular JIA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 27389402

Group type: EXPERIMENTAL
Intervention: NGF-ECB implants
Number of subjects: 4
Study: 27389410

Group type: EXPERIMENTAL
Intervention: Emergency Department Mental Health Clinical Pathway (EDMHCP)
Number of subjects: 0
Study: 27390310

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ESSPRI (European League Against Rheumatism Sjögren's Syndrome Patient Reported Index)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index)
Number of subjects: 120
Study: 27390845

Group type: EXPERIMENTAL
Intervention: Apoptotic CTCs in follow-up samples
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CTC clusters in follow-up samples
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: WBC-CTCs presence
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Apoptotic CTCs or clusters at any time-point
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CTC clusters at baseline
Number of subjects: 52
Study: 27390847

Group type: EXPERIMENTAL
Intervention: AVDCX regimen (cisplatin 25-35 mg/m2, docetaxel 25-35 mg/m2, capecitabine 1,600 mg/m2, bevacizumab 7.5 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AVDCX regimen at maximum tolerated dose (MTD)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AVDCX regimen
Number of subjects: 22
Study: 27391216

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study: 27391902

Group type: EXPERIMENTAL
Intervention: Calcium-free fluid with magnesium concentration of 1.50 mmol/l
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High magnesium containing fluid (3,000 ml/h)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ordinary dialysis fluid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcium-free fluid with magnesium concentration of 0.75 mmol/l
Number of subjects: 45
Study: 27392380

Group type: EXPERIMENTAL
Intervention: Active Classroom Instruction (ACI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal Classroom Instruction (NCI)
Number of subjects: 32
Study: 27392483

Group type: EXPERIMENTAL
Intervention: MK8245 (liver-specific SCD-1 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct anti-viral agents and interferon-alpha therapy
Number of subjects: 0
Study: 27394384

Group type: EXPERIMENTAL
Intervention: Near-continuous glucose monitoring technology
Number of subjects: 24

Group type: COMPARATOR
Intervention: Gold standard Yellow Springs Instrument (YSI)
Number of subjects: 24
Study: 27395070

Group type: EXPERIMENTAL
Intervention: ST elevation acute coronary syndrome (STE-ACS)
Number of subjects: 5140

Group type: EXPERIMENTAL
Intervention: Non-ST elevation acute coronary syndrome (NSTE-ACS)
Number of subjects: 5140

Group type: COMPARATOR
Intervention: Older patients (age > 65)
Number of subjects: 5140
Study: 27395381

Group type: EXPERIMENTAL
Intervention: PPH-protocols
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Guideline recommendations in protocols
Number of subjects: 18
Study: 27396777

Group type: EXPERIMENTAL
Intervention: Implantable intravascular delivery system for treprostinil infusion
Number of subjects: 60
Study: 27398025

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m(2) on days 1 and 8
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m(2) on days 1-14
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1102
Study: 27398272

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 15
Study: 27398407

Group type: EXPERIMENTAL
Intervention: Wearable artificial kidney
Number of subjects: 10
Study: 27399966

Group type: EXPERIMENTAL
Intervention: Chinese population (1,659 cases)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: European population (4,036 cases)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Replication study in Chinese (3,043 cases)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Replication study in European (2,643 cases)
Number of subjects: 1659

Group type: COMPARATOR
Intervention: Comparison of risk allele frequencies and genetic risk scores
Number of subjects: 1659
Study: 27399982

Group type: EXPERIMENTAL
Intervention: Intravenous polyspecific immunoglobulin G (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 0
Study: 27400222

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks thereafter up to 360 weeks
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 310
Study: 27400814

Group type: EXPERIMENTAL
Intervention: aortic pulse wave velocity (aPWV)
Number of subjects: 627
Study: 27400896

Group type: EXPERIMENTAL
Intervention: Combination therapy of pravastatin, zoledronic acid, and lonafarnib
Number of subjects: 37
Study: 27400898

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter aortic valve replacement
Number of subjects: 583
Study: 27400907

Group type: EXPERIMENTAL
Intervention: Self-reported exacerbations
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Single-physician chart review
Number of subjects: 409

Group type: COMPARATOR
Intervention: Central adjudication by a committee (reference standard)
Number of subjects: 409
Study: 27401348

Group type: EXPERIMENTAL
Intervention: Haemodialysis Public-Private Partnership Programme (HD-PPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes through face-to-face interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical outcomes from patient records
Number of subjects: 0
Study: 27401360

Group type: EXPERIMENTAL
Intervention: SmartPill(®)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Prokinetics, laxatives, and physiotherapy
Number of subjects: 65
Study: 27401581

Group type: COMPARATOR
Intervention: Brain dead patients
Number of subjects: 11
Study: 27402060

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Docetaxel as first subsequent therapy (FST)
Number of subjects: 546

Group type: COMPARATOR
Intervention: No subsequent therapy
Number of subjects: 546
Study: 27402093

Group type: EXPERIMENTAL
Intervention: GSK2647544, administered at a twice-daily dose of 102 mg, at steady state.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 4
Study: 27402170

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system blockers (including angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, dual therapy, and statins)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study: 27402391

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 27402559

Group type: EXPERIMENTAL
Intervention: GPS speed and grade (corrected)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GPS speed and uncorrected grade
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reference speed and grade (actual)
Number of subjects: 30
Study: 27402854

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent implantation with intravascular ultrasound evaluation
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent implantation with dissection
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Residual stent edge dissection
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Smaller effective lumen area in lesions with dissection
Number of subjects: 2062
Study: 27402890

Group type: EXPERIMENTAL
Intervention: Intermediate allele carriers (27-35 CAG)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Controls (<27 CAG)
Number of subjects: 657
Study: 27402910

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 3188

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 3188

Group type: EXPERIMENTAL
Intervention: Gonadotrophin plus IUI
Number of subjects: 3188

Group type: EXPERIMENTAL
Intervention: PCOS male partners
Number of subjects: 3188

Group type: COMPARATOR
Intervention: UI male partners
Number of subjects: 3188
Study: 27403127

Group type: EXPERIMENTAL
Intervention: RRx-001 pretreatment followed by platinum doublets
Number of subjects: 1

Group type: COMPARATOR
Intervention: Platinum doublets
Number of subjects: 1
Study: 27403291

Group type: EXPERIMENTAL
Intervention: Increased Periodic repolarisation dynamics (PRD) under resting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRD identified a new high-risk group of post-MI patients with preserved LVEF (>35%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic strategies in high-risk post-MI patients with LVEF 36-50% identified by PRD
Number of subjects: 0
Study: 27403301

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae I-3856 (1000 mg per day)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae I-3856 (1000 mg per day) in IBS-C subgroup
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo in IBS-C subgroup
Number of subjects: 379
Study: 27403334

Group type: EXPERIMENTAL
Intervention: Radiolabelled certolizumab pegol (CZP)
Number of subjects: 20
Study: 27403996

Group type: COMPARATOR
Intervention: Subfoveal choroidal thickness in choroideremia patients (42 eyes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Subfoveal choroidal thickness in age- and refraction-matched male controls (40 eyes)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Presence of outer retinal tubulations in eyes with choroideremia
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Correlation between RPE AF and outer nuclear layer thickness
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Quality of AF and integrity of ellipsoid zone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Subfoveal choroidal thickness at end-stage retinal degeneration
Number of subjects: 39
Study: 27404453

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (150 mg/m² every 2 weeks) in combination with cisplatin, capecitabine, and gemcitabine (PAXG regimen)
Number of subjects: 24
Study: 27404676

Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension management (specific intervention details not provided)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Children with pulmonary hypertension (specific intervention details not provided)
Number of subjects: 220
Study: 27404941

Group type: EXPERIMENTAL
Intervention: CEA TCB (T-cell-bispecific monoclonal antibody)
Number of subjects: 0
Study: 27404999

Group type: EXPERIMENTAL
Intervention: HPV-positive men (overall)
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: HIV-positive men
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Circumcised men
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: Overweight HIV-positive men (BMI > 25)
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Circumcision status
Number of subjects: 1813
Study: 27405306

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR in patients with acromegaly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasireotide SC in patients with Cushing's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasireotide SC in patients with acromegaly
Number of subjects: 0
Study: 27405442

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 12
Study: 27405652

Group type: EXPERIMENTAL
Intervention: COPD grades 1/2
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: COPD grade 3
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: COPD grade 4
Number of subjects: 6778

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: COPD grades 1-4
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 6778
Study: 27405963

Group type: EXPERIMENTAL
Intervention: Women with diabetes (SEVR 161% ± 26%)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control subjects (men and women without diabetes)
Number of subjects: 86
Study: 27406214

Group type: EXPERIMENTAL
Intervention: MSP database
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: DAD database
Number of subjects: 1031
Study: 27406602

Group type: EXPERIMENTAL
Intervention: LAA electric isolation and occlusion during AF ablation
Number of subjects: 22

Group type: COMPARATOR
Intervention: AF ablation alone (Control group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LAA electric isolation and occlusion
Number of subjects: 22
Study: 27406645

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-CPAP therapy assessment
Number of subjects: 0
Study: 27406646

Group type: EXPERIMENTAL
Intervention: Optimal care (all eligible guideline-indicated treatments)
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: Acute aspirin
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: Aspirin at discharge
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: Statins at discharge
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: Smoking cessation advice
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 357228

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 357228
Study: 27406936

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Gardasil)
Number of subjects: 59
Study: 27407039

Group type: EXPERIMENTAL
Intervention: Clinician-reported diagnoses of comorbid conditions
Number of subjects: 197

Group type: COMPARATOR
Intervention: Mini-International Neuropsychiatric Interview, parent version diagnoses
Number of subjects: 197
Study: 27407117

Group type: EXPERIMENTAL
Intervention: Standardized mixed-meal tolerance tests (MMTT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Standardized arginine stimulation tests (AST)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Frequently sampled intravenous glucose tolerance test (FSIGT)
Number of subjects: 62
Study: 27408945

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0